Horizon Therapeutics (Nasdaq:HZNP) - 주가, 뉴스 및 분석

HZNP 주식 개요

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. 자세한 내용

HZNP 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	3/6
과거 실적	1/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 52.1% 에서 거래

수익은 매년 16.43% 증가할 것으로 예상됩니다.

위험 분석

재무 결과에 영향을 미치는 대규모 일회성 항목

이익 마진 (12%) 작년보다 낮습니다 (20.1%)

Horizon Therapeutics Public Limited Company 경쟁사

United Therapeutics

NasdaqGS:UTHR

US$16.1b

Neurocrine Biosciences

NasdaqGS:NBIX

US$12.1b

Biogen

NasdaqGS:BIIB

US$22.6b

Sarepta Therapeutics

NasdaqGS:SRPT

US$10.2b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Horizon Therapeutics
과거 주가
현재 주가	US$116.30
52주 최고치	US$116.38
52주 최저치	US$60.03
베타	1.01
11개월 변경	0.76%
3개월 변경 사항	12.37%
1년 변경 사항	82.80%
33년 변화	45.18%
5년 변화	505.10%
IPO 이후 변화	1,171.04%

최근 뉴스 및 업데이트

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

주주 수익률

	HZNP	US Biotechs	US 마켓
7D	0.06%	-6.5%	-1.0%
1Y	82.8%	14.6%	30.3%

수익률 대 산업: HZNP 지난 1년 동안 14.6 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: HZNP 지난 1년 동안 30.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is HZNP's price volatile compared to industry and market?
HZNP volatility
HZNP Average Weekly Movement	2.0%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: HZNP 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: HZNP 의 주간 변동성( 2% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2005	2,190	Tim Walbert	www.horizontherapeutics.com

Horizon Therapeutics Public Limited Company 기본 사항 요약

Horizon Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
HZNP 기본 통계
시가총액	US$26.63b
수익(TTM)	US$438.00m
수익(TTM)	US$3.64b

60.8x

P/E 비율

7.3x

P/S 비율

HZNP 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
HZNP 손익 계산서(TTM)
수익	US$3.64b
수익 비용	US$824.98m
총 이익	US$2.82b
기타 비용	US$2.38b
수익	US$438.00m

최근 보고된 수익

Jun 30, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	1.91
총 마진	77.36%
순이익 마진	12.02%
부채/자본 비율	48.2%

HZNP 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

HZNP 주식 개요

보상

위험 분석

Horizon Therapeutics Public Limited Company 경쟁사

NasdaqGS:UTHR

US$16.1b

NasdaqGS:NBIX

US$12.1b

NasdaqGS:BIIB

US$22.6b

NasdaqGS:SRPT

US$10.2b

가격 내역 및 성능

최근 뉴스 및 업데이트

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Recent updates

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan

Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process

Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease

Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion.

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Investor sentiment improved over the past week

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease

Insufficient new directors

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Investor sentiment improved over the past week

Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease

Executive VP & Chief Strategy Officer exercised options and sold US$348k worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted)

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares.

Horizon Therapeutics announces $500M buyback program

Horizon Therapeutics to expand footprint in Ireland

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Horizon Therapeutics: This Core Biotech Company Is On Sale

Consensus revenue estimates fall by 10%

Executive VP & Chief Strategy Officer notifies of intention to sell stock

Price target decreased to US$114

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)